| Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test |
2021-01-28 |
| Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund |
2021-01-28 |
| Ukko–Bayer: investment, 202101 financing round Series B totalling $40m incl lead investor Leaps by Bayer |
2021-01-27 |
| Ukko–SEVERAL: investment, 202101 financing round Series B $40m led by Leaps by Bayer |
2021-01-27 |
| GeneQuine–Brandenburg (govt): grant, 202101 grant €900k from investment bank of federal state Brandenburg |
2021-01-26 |
| GeneQuine–High-Tech Gründerfonds: investment, 202101 financing round Series A totalling €5.4m incl existing + co-investor HTGF |
2021-01-26 |
| GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA |
2021-01-26 |
| GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences |
2021-01-26 |
| GeneQuine–Samum: credit, 202101 convertible loans totalling €2.75m from Pacira BioSciences Inc + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Samum: investment, 202101 financing round Series A totalling €5.4m incl co-investor Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences |
2021-01-26 |
| Microcaps–SEVERAL: investment, 202101 seed financing round CHF5m co-led by Helvetica Capital + ZKB |
2021-01-26 |
| Cellvie–Forever Healthy: investment, 202101 seed financing round totalling $5m incl lead investor Kizoo Technology Capital |
2021-01-25 |
| Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital |
2021-01-25 |
| CureVac–SEVERAL: investment, 202101–202102 follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share |
2021-01-25 |
| i3 Membrane–High-Tech Gründerfonds: investment, 202101 financing round totalling 7-figure € sum inkl existing investor HTGF |
2021-01-25 |
| i3 Membrane–OTHER: investment, 202101 financing round totalling 7-figure € sum incl three private investors |
2021-01-25 |
| i3 Membrane–SEVERAL: investment, 202101 financing round 7-figure € sum from HTGF + three private investors |
2021-01-25 |
| TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund |
2021-01-25 |
| TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital |
2021-01-25 |
| Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx |
2021-01-21 |
| AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones |
2021-01-20 |
| Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.95m at Nasdaq |
2021-01-20 |
| Relief Therapeutics–MC Services: public relations, 202101 service existent by MC Services |
2021-01-20 |
| LignoPure–Hamburg (govt): investment, 202101 seed financing round totalling €2.2m incl investor Innovationsstarter Fonds Hamburg GmbH |
2021-01-18 |
| LignoPure–High-Tech Gründerfonds: investment, 202101 seed financing round totalling €2.2m incl investor HTGF |
2021-01-18 |
| LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG |
2021-01-18 |
| LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG |
2021-01-18 |
| IO Biotech–HBM: investment, 202101 financing round Series B totalling €127m incl new + lead investor HBM Healthcare Investments |
2021-01-13 |
| IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments |
2021-01-13 |
| Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors |
2021-01-13 |
| Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share |
2021-01-12 |
| Corat Therapeutics–Lower Saxony (govt): investment, 202101 2nd financing round incl existing investor NBank Capital |
2021-01-12 |
| Corat Therapeutics–OTHER: investment, 202101 2nd financing round incl private investors from Braunschweig |
2021-01-12 |
| Corat Therapeutics–SEVERAL: investment, 202101 2nd financing round from NBank Capital + private investors |
2021-01-12 |
| Delfi Diagnostics–Allianz: investment, 202101 financing round Series A totalling $100m incl existing + co-investor AV8 Ventures |
2021-01-12 |
| Delfi Diagnostics–SEVERAL: investment, 202101 financing round Series A $100m led by OrbiMed |
2021-01-12 |
| Addex–SEVERAL: investment, 202101 capital increase global offering $11.5m with 6.9m new shares (thereof 6.75m in form of ADSs |
2021-01-11 |
| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI |
2021-01-11 |
| Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED |
2021-01-11 |
| Labforward–2mag: investment, 202101 financing round Series B totalling >€5m incl new + co-investor 2mag |
2021-01-11 |
| Labforward–Peppermint: investment, 202101 financing round Series B totalling >€5m incl existing + co-investor Peppermint VenturePartners |
2021-01-11 |
| Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners |
2021-01-11 |
| Labforward–Tecan: investment, 202101 financing round Series B totalling >€5m incl €4m from new + lead investor Tecan resulting in 10% stake |
2021-01-11 |
| Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP |
2021-01-11 |
| Valo Health–Canada (govt): investment, 202101 financing round Series B totalling $190m incl lead investor PSP Investments |
2021-01-11 |
| Valo Health–HBM: investment, 202101 financing round Series B totalling $190m incl new + co-investor HBM Healthcare Investments |
2021-01-11 |
| Valo Health–SEVERAL: investment, 202101 financing round Series B $190m led by PSP Investments |
2021-01-11 |
| Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies |
2021-01-08 |
| AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck |
2021-01-07 |
| BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund |
2021-01-07 |
| BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital |
2021-01-07 |
| BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
| Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies |
2021-01-07 |
| Sterna Biologicals–SEVERAL: investment, 202101 financing round Series A 2nd closing €10m bringing total Series A to €22m |
2021-01-07 |
| Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp |
2021-01-06 |
| Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp |
2021-01-06 |
| Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 |
2021-01-06 |
| Novasep–Sartorius: investment, 202101– acquisition €na of Novasep’s chromatography process equipment division by Sartorius ANNOUNCED |
2021-01-06 |
| Senti Biosciences–Bayer: investment, 202101 financing round Series B totalling $105m incl new + lead investor Leaps by Bayer |
2021-01-06 |
| Senti Biosciences–SEVERAL: investment, 202101 financing round Series B $105m led by Leaps by Bayer |
2021-01-06 |
| Terns Pharmaceuticals–Samsara Capital: investment, 202101 financing round Series C totalling $87m incl co-investor Samsara Capital |
2021-01-05 |
| Terns Pharmaceuticals–SEVERAL: investment, 202101 financing round Series C $87m led by Deerfield Management |
2021-01-05 |
| Arvelle Therapeutics–Angelini: investment, 202101– acquisition merger up to $960m in cash with $610m after approval of cenobamate + $350m milestones |
2021-01-04 |
| Somatex Medical Technologies–Hologic: investment, 202101 acquisition $64m of Somatex by Hologic |
2021-01-04 |
| Biosun Biochemicals–BRAIN Biotech: investment, 202101 acquisition 100% €na by BRAIN AG |
2021-01-01 |
| Cutanos–Max Planck: topical drug delivery technology, 202101– license excl to LC-TDS technology from Max Planck Innovation |
2021-01-01 |
| Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use |
2021-01-01 |
| Cajal Neuroscience–Evotec: investment, 202012 existent Evotec owns 1.82% of voting rights |
2020-12-31 |
| Dark Blue Therapeutics–Evotec: investment, 202012 existent Evotec owns 18.67% of voting rights |
2020-12-31 |
| Mission BioCapital–Evotec: investment, 202012 existent Evotec owns 7.22% of voting rights of Mission BioCapital V LP |
2020-12-31 |
| NephThera–Evotec: investment, 202012 existent Evotec owns 50.00% of voting rights |
2020-12-31 |
| SomaLogic–Novartis: investment, 202012 financing round Series A 2nd closing totalling addit $81m incl Novartis |
2020-12-22 |
| SomaLogic–SEVERAL: investment, 202012 financing round Series A 2nd closing additional $81m bringing total Series A to $204m or $214m |
2020-12-22 |
| Evotec–Alloy Therapeutics: transgenic mouse technolgy, 202012– supply access to ATX-Gx platform to expand Evotec antibody discovery platform |
2020-12-21 |
| Peptilogics–Angermayer Group: investment, 202012 financing round Series B totalling $35.4m incl new + lead investor Presight Capital |
2020-12-21 |
| Peptilogics–SEVERAL: investment, 202012 financing round Series B $35.4m led by Presight Capital |
2020-12-21 |
| Cadent Therapeutics–Novartis: investment, 202012– acquisition $210m upfront + $560m milestones ANNOUNCED |
2020-12-17 |
| ECBF–SEVERAL: investment, 202012–202202 raising of additional €125m + final closing of fund at €300m |
2020-12-16 |
| Exo Therapeutics–Novartis: investment, 202012 financing round Series A totalling $25m incl investor Novartis Venture Fund |
2020-12-16 |
| Exo Therapeutics–SEVERAL: investment, 202012 financing round Series A $25m incl Newpath Partners + NVF + CRV + 6 Dimensions Capital |
2020-12-16 |
| Neuron23–SEVERAL: investment, 202012 financing round Series B $80m led by new investor Redmile Group |
2020-12-16 |
| ECBF–Neste: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Neste |
2020-12-15 |
| ECBF–Nestlé: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Nestlé |
2020-12-15 |
| ECBF–North Rhine-Westphalia (govt): investment, 202012 2nd closing with additional sum totalling €93m incl new investor NRW.Bank |
2020-12-15 |
| ECBF–OTHER: investment, 202012 2nd closing with additional sum totalling €93m incl undisclosed family office as new investor |
2020-12-15 |
| ECBF–SEVERAL: investment, 202012 2nd closing with additional €93m from new investors bringing total to €175m |
2020-12-15 |
| ECBF–Volkswohl Bund: investment, 202012 2nd closing with additional sum totalling €93m incl new investor Volkswohl Bund Versicherungen |
2020-12-15 |
| MYR GmbH–Gilead: investment, 202012 acquisition €1.15b in cash + €300m milestones of MYR GmbH by Gilead Sciences Inc |
2020-12-10 |
| NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer |
2020-12-10 |
| Resolve Biosciences–Alafi Capital: investment, 202012 financing round Series A totalling $24m incl co-investor Alafi Capital |
2020-12-10 |
| Resolve Biosciences–Bioscribe: public relations, 202012 service existent by Bioscribe |
2020-12-10 |
| Resolve Biosciences–High-Tech Gründerfonds: investment, 202012 financing round Series A totalling $24m incl co-investor HTGF |
2020-12-10 |
| Resolve Biosciences–MasterMind Advisory Services: investment, 202012 financing round Series A totalling $24m incl co-lead investor MasterMind |
2020-12-10 |
| Resolve Biosciences–PERSON: investment, 202012 financing round Series A totalling $24m incl co-investor John Shoffner |
2020-12-10 |
| Resolve Biosciences–PS Capital Management: investment, 202012 financing round Series A totalling $24m incl co-lead investor PS Capital |
2020-12-10 |
| Resolve Biosciences–SEVERAL: investment, 202012 financing round Series A $24m co-led by PS Capital Management + MasterMind Advisory Services |
2020-12-10 |
| Curexsys–Evotec: investment, 202012 seed financing round totalling €8.2m incl Evotec acquiring 37% equity stake |
2020-12-09 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 10 11 12 ... 48 49 50 
Date![Picture [iito] No Content Marketing 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
